Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Comparative Effectiveness of Intensity-Modulated Versus 3D Conformal Radiation Therapy Among Medicare Patients with Stage III Lung Cancer

Comparative Effectiveness of Intensity-Modulated Versus 3D Conformal Radiation Therapy Among... ORIgINAL ARTICLE Comparative Effectiveness of Intensity-Modulated Versus  3D Conformal Radiation Therapy Among Medicare Patients  with Stage III Lung Cancer Aileen B. Chen, MD, MPP,* Ling Li, MSPH,† Angel Cronin, MS,† and Deborah Schrag, MD, MPH† over 5 years, some achieve long-term survival with aggressive Introduction: The clinical benefit of intensity-modulated radiation combination therapies, including radiation therapy. therapy (IMRT) compared to 3D conformal radiation (3D-RT) has The adoption of advanced radiation therapy technolo- not been well established for locally advanced non–small-cell lung gies, such as 3D conformal radiation (3D-RT) and intensity- cancer (NSCLC). modulated radiation therapy (IMRT) have allowed radiation Methods: Using SEER-Medicare, we identified Medicare benefi- oncologists to more accurately target tumor volumes while ciaries diagnosed with stage III NSCLC who received potentially reducing risk of toxicity to surrounding normal tissues. In curative (≥ 25 fractions) thoracic IMRT or 3D-RT from 2002–2009. a prior study, we found that adoption of 3D-RT, made pos- Overall survival and number of hospital days within 90 days of radia- sible by CT-based treatment planning, was associated with tion were analyzed using Cox proportional hazard and negative bino- improved outcomes among patients with stage III non–small- mial regression models, respectively. Propensity score adjustment cell lung cancer (NSCLC) receiving thoracic radiation (TRT). was used to control for clinical and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Comparative Effectiveness of Intensity-Modulated Versus 3D Conformal Radiation Therapy Among Medicare Patients with Stage III Lung Cancer

Journal of Thoracic Oncology , Volume 9 (12) – Dec 1, 2014

Loading next page...
 
/lp/wolters-kluwer-health/comparative-effectiveness-of-intensity-modulated-versus-3d-conformal-r04t2a2niY

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2014 by the International Association for the Study of Lung Cancer
ISSN
1556-0864

Abstract

ORIgINAL ARTICLE Comparative Effectiveness of Intensity-Modulated Versus  3D Conformal Radiation Therapy Among Medicare Patients  with Stage III Lung Cancer Aileen B. Chen, MD, MPP,* Ling Li, MSPH,† Angel Cronin, MS,† and Deborah Schrag, MD, MPH† over 5 years, some achieve long-term survival with aggressive Introduction: The clinical benefit of intensity-modulated radiation combination therapies, including radiation therapy. therapy (IMRT) compared to 3D conformal radiation (3D-RT) has The adoption of advanced radiation therapy technolo- not been well established for locally advanced non–small-cell lung gies, such as 3D conformal radiation (3D-RT) and intensity- cancer (NSCLC). modulated radiation therapy (IMRT) have allowed radiation Methods: Using SEER-Medicare, we identified Medicare benefi- oncologists to more accurately target tumor volumes while ciaries diagnosed with stage III NSCLC who received potentially reducing risk of toxicity to surrounding normal tissues. In curative (≥ 25 fractions) thoracic IMRT or 3D-RT from 2002–2009. a prior study, we found that adoption of 3D-RT, made pos- Overall survival and number of hospital days within 90 days of radia- sible by CT-based treatment planning, was associated with tion were analyzed using Cox proportional hazard and negative bino- improved outcomes among patients with stage III non–small- mial regression models, respectively. Propensity score adjustment cell lung cancer (NSCLC) receiving thoracic radiation (TRT). was used to control for clinical and

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Dec 1, 2014

There are no references for this article.